AbCellera Biologics (ABCL) Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbCellera Biologics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABCL shares.
View ABCL analyst ratings or view top-rated stocks.

8 Wall Street analysts have issued 1 year target prices for AbCellera Biologics' stock. Their ABCL share price forecasts range from $15.00 to $34.00. On average, they anticipate the company's stock price to reach $25.57 in the next year. This suggests a possible upside of 266.9% from the stock's current price.
View analysts price targets for ABCL or view top-rated stocks among Wall Street analysts.

AbCellera Biologics' stock was trading at $10.13 on January 1st, 2023. Since then, ABCL shares have decreased by 31.2% and is now trading at $6.97.
View the best growth stocks for 2023 here.

AbCellera Biologics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 26,620,000 shares, an increase of 8.5% from the April 30th total of 24,530,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is currently 13.5 days. Currently, 13.5% of the company's stock are short sold.
View AbCellera Biologics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ABCL earnings forecast.

AbCellera Biologics Inc. (NASDAQ:ABCL) announced its quarterly earnings data on Thursday, May, 4th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.02. The company had revenue of $12.20 million for the quarter, compared to analysts' expectations of $12.11 million. AbCellera Biologics had a negative net margin of 27.71% and a negative trailing twelve-month return on equity of 4.09%. The firm's revenue was down 96.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.54 EPS.

ETFs with the largest weight of AbCellera Biologics (NASDAQ:ABCL) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), TrueShares Technology, AI & Deep Learning ETF (LRNZ), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), iShares Biotechnology ETF (IBB), Renaissance IPO ETF (IPO) and

(ABCL) raised $356 million in an initial public offering on Friday, December 11th 2020. The company issued 23,000,000 shares at $14.00-$17.00 per share. Credit Suisse, Stifel, Berenberg, SVB Leerink and BMO Capital Markets acted as the underwriters for the IPO.

AbCellera Biologics trades on the NASDAQ under the ticker symbol "ABCL."

AbCellera Biologics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (6.89%), BlackRock Inc. (4.74%), Credit Suisse AG (1.60%), State Street Corp (1.17%), Federated Hermes Inc. (1.01%) and Renaissance Technologies LLC (0.97%). Insiders that own company stock include Andrew Booth, Andrew Lo, Carl L G Hansen, Holdings Ltd Thermopylae, John Hamer, John S Montalbano, Michael R Hayden and Veronique Lecault.
View institutional ownership trends.

Shares of ABCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABCL stock can currently be purchased for approximately $6.97.

AbCellera Biologics (NASDAQ:ABCL) has a market capitalization of $2.01 billion and generates $485.42 million in revenue each year. The company earns $158.52 million in net income (profit) each year or ($0.18) on an earnings per share basis.

The company employs 386 workers across the globe.

The official website for the company is www.abcellera.com. The company can be reached via phone at 604-559-9005 or via email at ir@abcellera.com.